ASSESSING THE IMPLEMENTABILITY OF REGULATORY AGENCIES' GUIDANCE ON DIVERSITY IN CLINICAL TRIALS

被引：0
|
作者：
Metcalfe, R. [1 ]
Reshef, S. [2 ]
Park, J. [1 ]
机构：
[1] Core Clin Sci, Vancouver, BC, Canada
[2] Teva Branded Pharmaceut Prod R&D Inc, Epidemiol & Global Hlth Econ & Outcomes Res, Parsippany, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR87
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [1] Carrots or Sticks: An Industry Perspective on the Significance of Regulatory Guidance in Promoting Participant Diversity in Clinical Trials
    Peters, Ubong
    Spahn, Jessica
    Patel, Shilpen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 116 (01): : 115 - 117
  • [2] Guidance for the regulatory status of allergen extracts in clinical trials
    Diamant, Zuzana
    van Maaren, Maurits
    van Wijk, Roy Gerth
    Brouwers, Jacobus R. B. J.
    Pieterses, Herman
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (04) : 1223 - 1225
  • [3] FDA Proposes Guidance for Increasing Diversity in Clinical Trials
    Harris, Emily
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (07):
  • [4] Assessing Participant Diversity in Acne Clinical Trials
    Gupta, Rohit
    Roy, Cayla
    Doan, Hung Q.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (07) : 797 - 798
  • [5] Understanding implementability in clinical trials: a pragmatic review and concept map
    Cumpston, Miranda S.
    Webb, Steven A.
    Middleton, Philippa
    Sharplin, Greg
    Green, Sally
    TRIALS, 2021, 22 (01)
  • [6] Understanding implementability in clinical trials: a pragmatic review and concept map
    Miranda S. Cumpston
    Steven A. Webb
    Philippa Middleton
    Greg Sharplin
    Sally Green
    Trials, 22
  • [7] Clinical trials of lasers for toenail onychomycosis: The implications of new regulatory guidance
    Gupta, Aditya K.
    Foley, Kelly A.
    Daigle, Deanne
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (03) : 264 - 270
  • [8] Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?
    C. Sampaio
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 339 - 340
  • [9] Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?
    Sampaio, C.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (04): : 339 - 340
  • [10] Assessing subject diversity by condition and trial phase in clinical trials
    Gorrepati, Pavane L.
    Smith, Gideon P.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2023, 62 (02) : E65 - E67
12345